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Caboxamycin, a new antibiotic of the benzoxazole
family produced by the deep-sea strain Streptomyces
sp. NTK 937*
Claudia Hohmann1,8, Kathrin Schneider2,8, Christina Bruntner1, Elisabeth Irran2, Graeme Nicholson3,
Alan T Bull4, Amanda L Jones5, Roselyn Brown5, James EM Stach5, Michael Goodfellow5, Winfried Beil6,
Marco Kra¨mer7, Johannes F Imhoff7, Roderich D Su¨ssmuth2 and Hans-Peter Fiedler1
Caboxamycin, a new benzoxazole antibiotic, was detected by HPLC-diode array screening in extracts of the marine strain
Streptomyces sp. NTK 937, which was isolated from deep-sea sediment collected in the Canary Basin. The structure of
caboxamycin was determined by mass spectrometry, NMR experiments and X-ray analysis. It showed inhibitory activity against
Gram-positive bacteria, selected human tumor cell lines and the enzyme phosphodiesterase.
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INTRODUCTION
A set of 600 actinomycetes isolated from marine sediments from various
sites in the Atlantic and Pacific Oceans were screened using our HPLC-
diode array technology for the production of bioactive secondary
metabolites. It is becoming increasingly clear that actinomycetes isolated
from marine habitats are a rich source of new natural products,
including drug candidates.1–5 Extracts from the culture filtrate of strain
NTK 937 showed a prominent peak in the HPLC-diode array analysis
that had an unusual UV-visible spectrum, albeit it was similar to that of
nataxazole from our HPLC-UV-Vis database which contains 867
entries, mostly antibiotics.6 Nataxazole, a new member of the benzox-
azole family of antibiotics, was extracted from terrestrial Streptomyces
sp. Tu¨ 6176.7 Nataxazole has a structure similar to that of benzoxazoles
UK-18 and AJI9561,9 which were derived from Streptomyces strains, and
were shown to have potent anti-tumor properties. The similarity of the
UV-visible spectrum of the metabolite produced by strain NTK 937 to
nataxazole underlines its structural relationship to benzoxazoles; the
new compound was named caboxamycin (1) composed from the
strain’s collection site, the Canary Basin and the benzoxazole scaffold
of its structure, which is shown in Figure 1. Herein, we report on the
taxonomy of the producing strain, the fermentation, isolation and
structural elucidation of caboxamycin and its biological activities.
RESULTS
Taxonomy of the producing strain
The chemical and morphological properties of strain NTK 937 were
consistent with its classification in the genus Streptomyces.10 The
organism formed an extensively branched substrate mycelium, straight
spore chains on the aerial mycelium, contained hexa- and octa-
hydrogenated menaquinones with nine isoprene units as the predo-
minate isoprenologues, and gave whole-cell hydrolysates rich in
LL-diaminopimelic acid. Comparison of an almost complete 16S
rRNA sequence of strain NTK 937 with corresponding sequences of
Streptomyces type strains showed that it formed a distinct phyletic line
in the Streptomyces 16S rRNA gene tree.
Screening, fermentation and isolation
When grown in the 20-liter fermentor strain NTK 937 reached a
maximal biomass of 12 mg dry weight per ml after 5 days of
incubation. Production of 1 started at 72 h, reaching a maximal
yield of 15 mg l1 after incubation for 5 days. The HPLC elution
profile of the corresponding culture filtrate is shown in Figure 2. 1 was
isolated from the culture filtrate by separation on an Amberlite XAD-
16 column; the extracts were concentrated to an aqueous residue and
extracted with ethylacetate and concentrated in vacuo to dryness. The
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crude product was purified by chromatography on a diol-modified
silica gel column followed by chromatography on a Sephadex LH-20
and Toyopearl HW-40S column. 1 was obtained as a white, yellow-
fluorescent powder after concentrated to dryness.
Structural elucidation
The mass spectrum derived from the HPLC-ESI-MS chromatograms
revealed the molecular mass for 1 [(M+H)+¼256.0]. The exact
molecular mass was determined by high-resolution ESI-FT-ICR-MS
as 256.06010 Da [(M+H)+] (1), this corresponds to the molecular
formulae C14H9NO4 (1) [(M+H)
+
theor¼256.06043; Dm¼1.29 p.p.m.].
The ESI-FTICR-MS measurement of 1 showed an additional mole-
cular mass of 564.02409 Da [(M-3H+Fe+H)+]. This corresponds well
with the molecular formula C28H16N2O8Fe [(2M-3H+Fe+H)
+
theor
¼564.02506; Dm¼1.72 p.p.m.] and suggests that the compound is
able to complex metal ions. The physico-chemical properties of 1 are
summarized in Table 1.
The 1H-NMR-spectrum of 1 showed seven signals in the aromatic
region between 8.2 and 7 p.p.m. and one broad signal at 11.8 p.p.m.
13C-NMR and DEPT spectra revealed the presence of seven aromatic
CH groups and seven quaternary carbons between 170 and 110 p.p.m.
The correlation of 1H-NMR-signals to the corresponding C-atoms
was determined in a Heteronuclear Multiple Quantum Coherence
NMR experiment. Seven signals were found in accordance with the
DEPT spectrum. Compared to the molecular formula, C14H9N1O4,
two protons should be bound to heteroatoms (OH or NH),
one of which giving a broad signal at 11.8 p.p.m. in the 1H-NMR-
spectrum.
The structure was fully elucidated using COSY and HMBC spectra.
The 1H-1H-COSY experiment revealed two spin systems, one of which
showed correlations from H-4 to H-6 and the other one from H-10 to
H-13 (Figure 3). The structure was fully elucidated using the HMBC
spectrum; structure consists of two constituents, a salicylic acid and a
hydroxy-anthranilic acid connected by a ring closure between the
carboxylic acid group of the salicylic acid and the hydroxyl- and amin-
groups of the hydroxy-anthranilic acid (Figure 1). The correlations
from H-5¢ to C-2¢¢, C-3¢a and C-7¢, from H-6¢ to C-4¢ and C-7¢a and
from H-7¢ to C-3¢a and C-5¢, shown in Figure 3, together with the
chemical shifts of C-3¢a, 138.7 p.p.m. and C-7¢a, 149.5 p.p.m., prove
the presence of a hydroxy-anthranilic acid, especially for the positions
of the nitrogen-, the oxygen-atoms and of the carboxylic acid group at
C-3¢a. The presence of a salicylic acid moiety was proven by the
connectivities from H-3 to C-1 and C-5, from H-4 to C-2 and C-6,
from H-5 to C-1 and C-3 and from H-6 to C-2¢, C-2 and C-4
(Figure 3). Comparing the NMR data obtained for 1, summarized in
Table 2, to the NMR data of known metabolites (Table 2) with a
similar structure; for example, AJI956111 (Figure 4), verifies the
structure of 1. Moreover, parallel to NMR studies, crystallization
experiments were performed with a single crystal obtained for
compound 1. Subsequent X-ray structural determination fully con-
firmed the structure of compound 1 (Figure 3).
Biological activity
Caboxamycin (1) showed antibiotic activity against the Gram-positive
bacteria Bacillus subtilis (IC50¼8mM), Staphylococcus lentus
(IC50¼20mM) and the yeast Candida glabrata (IC50¼117mM). Also
the biofilm formation of Staphylococcus xylosus was weakly inhibited.
A significant activity was present against the phytopathogenic bacteria
Xanthomonas campestris (IC50¼43mM) and Ralstonia solanacearum
(IC50¼176mM) and against the opportunistic pathogen Staphylococcus
epidermidis (IC50¼43mM). The corresponding data for chloramphe-
nicol (positive control prokaryotes) were: Bacillus subtilis
(IC50¼9mM), Staphylococcus lentus (IC50¼14mM), Xanthomonas cam-
pestris (IC50¼6mM), Ralstonia solanacearum (IC50¼75mM), Staphylo-
coccus epidermidis (IC50¼7mM) and for cycloheximide (positive
control eukaryotes): Candida glabrata (IC50¼4mM).
The cytotoxic effect of caboxamycin (1) was tested in different
tumor cell lines. It showed a moderate growth inhibitory activity
(IC50: 28.6–29.4mM) towards gastric adenocarcinoma (AGS), hepato-
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Figure 1 Structure of caboxamycin (1).
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Figure 2 HPLC analysis of a culture filtrate from Streptomyces sp. NTK 937
at a fermentation time of 120h, monitored at 310nm, and UV-visible
spectrum of caboxamycin (1), retention time 9.9min.
Table 1 Physico-chemical properties of caboxamycin (1)
1
Appearance White powder
Molecular weight 255
Molecular formula C14H9N1O4
ESI-FT-ICR MS (mz1)
Found 256.06010 (M+H)+
Calcd 256.06043 (M+H)+
UV lMeOHmax [nm]
(e [cm2 mmol1]) 212 (20), 243 (8.16), 257 (sh, 8.16), 263 (8.37),
273 (sh, 7.35), 292 (sh, 5.51), 305 (sh, 7.76),
331 (11.43), 342 (sh, 10.82)
IR nmax (cm1) 3466, 3088, 3046, 3006, 2956, 2920, 2850,
2676, 2570, 1690, 1633, 1591, 1546, 1486,
1433, 1296, 1264, 1247, 1239, 1183, 1155,
1065, 875, 752, 740, 724
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cellular carcinoma (Hep G2) and breast carcinoma cells (MCF7).
UK-1 (2) was more potent than 1 (Table 3).
Caboxamycin (1) is a weak inhibitor of bovine brain PDE
(IC50¼148mM) and only slightly inhibited human PDE-4B2
(IC50¼1.46 mM).
DISCUSSION
The benzoxazole core structure of caboxamycin (1) is part of the
natural products UK-1 (2) from Streptomyces sp. 517-02,8 AJI9561 (3)
from Streptomyces sp. AJI95619 and nataxazole (4) from Streptomyces
sp. Tu¨ 6176.7 2B4 showed potent cytotoxic activities against various
tumor cell lines whereas growth inhibition was not observed against
Gram-positive or Gram-negative bacteria, or against yeasts and fungi.
Furthermore, two derivatives of UK-1, Me-UK-1 (5) and DeMe-UK-1
(6), were prepared by methylation with methyl iodide and alkaline
hydrolysis, respectively;12 their structures are shown in Figure 4.
Interestingly, 6 exhibited anti-bacterial activity13 and 5 anti-fungal
activity.14
In the last decade efforts have been made to understand the selective
cytotoxic activity of UK-1 (2) towards cancer cells versus bacteria and
fungi, and for this purpose various synthetic derivates have been
prepared (Figure 5) and their biological activities evaluated and
compared.15–17 Reynolds et al.18 investigated the metal ion coordina-
tion by 2. It was shown that 2 bound divalent metal ions and DNA in
a divalent metal ion-dependent manner. It also bound to double-
stranded DNA 10 times more tightly in the presence of Mg2+ and
inhibited human topoisomerase II.16
It was demonstrated that the synthetic benzoxazole derivative 7,
which is the methyl ester of 1, retained the selectivity of the natural
product against cancer cells and therefore represents a minimum
structural pharmacophore.14 The synthetic derivative 8, which con-
stitutes the methyl ether of 1 and 9, which represents the decarboxy-
lated 1, did not exhibit any cytotoxic or anti-bacterial activities.15 It
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Figure 3 Selected 2D NMR correlations (a) and X-ray structure (b) of caboxamycin (1).
Table 2 1H and 13C NMR spectral data of caboxamycin (1)
and AJI9561 (3) 11 in DMSO-d6
1 in DMSO-d6 3 in DMSO-d6
No.
d (1H) [p.p.m.]
J in Hz
d (13C)
[p.p.m.]
d (1H) [p.p.m.]
J in Hz
d (13C)
[p.p.m.]
1 109.7 — 120.5
2 158.4 — 150.4
3 7.12 d (8.13) 117.3 7.06 d (8.0) 121.1
4 7.53 m 134.4 7.36 t (8.0) 131.8
5 7.07 t (7.23) 119.9 6.85 d (8.0) 128.7
6 8.00 d (7.61) 127.4 140.8
2¢ 163.6 161.5
3¢a 138.7 139.9
4¢ 121.8 118.7
5¢ 7.97 d (7.74) 127.2 8.37 d (7.6) 125.9
6¢ 7.54 m 125.3 7.59 t (7.6) 125.3
7¢ 8.07 d (8.00) 115.3 7.88 d (7.6) 113.9
7¢a 149.5 151.2
2¢¢ 165.6 162.8
3¢¢ a 141.4
4¢¢ 122.3
5¢¢ 8.21 d (8.0) 127.3
6¢¢ 7.58 d (8.0) 124.8
7¢¢ 7.94 d (8.0) 115.3
7¢¢ a 151.7
Me 2.86 s 21.3
OH 12.91 brs
COOH 11.7 br
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5:Me-UK-1:R1 = R2 = CH3; R3 = H
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Figure 4 Structures of benzoxazole metabolites from Streptomyces strains.
Table 3 Growth inhibitory activity (lg ml1) of caboxamycin (1)
and UK-1 (2) against selected human tumor cell lines
Cell line
1 2
GI50 TGI GI50 TGI
AGS 7.5 410a 0.8 1.9
Hep G2 7.4 410b 0.085 2.4
MCF7 7.3 410c 0.65 3.5
Abbreviations: GI50, 50% growth inhibition; TGI, 100% growth inhibition.
a72% inhibition at 10mg ml1.
b70% inhibition at 10mg ml1.
c80% inhibition at 10mg ml1.
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was shown that an appropriate substituent in position 4¢ of the
benzoxazole core is important for an efficient Mg2+-binding ability.
The described cytotoxic activity of the described natural product 1 and
the observation of an iron-intermediate with ESI-FT-ICR-MS are in
accordance with these results. UK-1 displays cytotoxic activity against
certain solid tumor-derived cell lines.15 Caboxamycin is less potent
than UK-1. Therefore the interaction between 2 and the Mg2+ ion may
be stronger than that of 1. Synthetic derived 1 has been described as an
intermediate in the synthesis of benzoxazole carboxamides, but its
biological activity has not been evaluated.19 The streptomycete meta-
bolite 1 and the evaluation of its biological activity add an element to the
investigations of synthetic derivatives of the natural product UK-1 (2).
A further benzoxazole natural product related to UK-1 family is
antibiotic A-33853 (10) which is produced by a Streptomyces strain;20
its structure is shown in Figure 6. Although benzoxazoles 2–6 are
composed of two molecules, hydroxy-anthranilic acid and one salicylic
acid, which form two ring closures resulting in the bis(benzoxazole)
structure, 10 consists of two molecules, hydroxy-anthranilic acid and
one 3-hydroxy-picolinic acid, which build one benzoxazole and one
amide bond. Interestingly, 10 showed anti-bacterial activity against
penicillin-resistant Staphylococcus and Streptococcus strains, and anti-
viral and anti-trichomonal activities in vitro.20 Unfortunately, data are
not available on the cytotoxic activity and the metal-binding ability of
10, hence it is not possible to consider the contributions of the various
structural elements to the biological activity.
Among biological activities of caboxamycin (1) the inhibition of
phosphodiesterases are notable. Phosphodiesterases are essential reg-
ulators of cyclic nucleotide signalling with diverse physiological
functions. PDE-4-selective inhibitors have therapeutic potential for
treating major diseases, such as asthmatic inflammation and chronic
obstructive pulmonary disease21,22 and several PDE-4 inhibitors have
reached the clinical trial of phases II and III status.22 The PDE-4B
enzyme is widely expressed in human inflammatory cells, negatively
regulates a wide range of pro-inflammatory and immune cells21,23 and
appears to be involved in the production of the tumor necrosis factor
TNF-a and other cytokines promoting the inflammatory response.22
Therefore, by inhibiting the PDE-4B enzyme, inflammatory response
is blocked or strongly reduced.
The results pointed out, that caboxamycin has a 10-fold stronger
inhibitory effect to the mixture of the three bovine PDE isoforms
(IC50¼148mM) than on the human PDE-4B2 (IC50¼1.46 mM). This
might be based on significantly stronger inhibition of PDE-2 and
PDE-10 by caboxamycin than PDE-4. Despite this weak inhibition, the
effect is notable because the effect against other phosphodiesterases
possibly may be much stronger than the measured effects against the
selection of enzymes tested. In addition, structural modifications of
the caboxamycin molecule may yield molecules demonstrating much
stronger effects. Structural modification according to the binding
properties to human PDE-4B2 already has successfully been carried
out with other PDE-4 inhibitors.22
METHODS
Producing organism and taxonomy
Strain NTK 937 was isolated from an Atlantic Ocean deep-sea sediment core
collected in 2001 at the southern edge of the Saharan debris flow near the
Canary Islands (27102¢392N, 18129¢022W) at a depth of 3814 m. Isolations
were made from the turbidite fraction of the core (0–38 cm from surface)
which was deposited approximately 1,000 years ago, but derived from older
(approximately 200 000 years) previously deposited sediment from further
upslope.11
Strain NTK 937 was examined using a combination of genotypic and
phenotypic procedures known to produce data of value in the delineation of
Streptomyces species.24,25
Fermentation and isolation
Batch fermentations of strain NTK 937 were carried out in a 20-liter fermentor
equipped with a turbine impeller system (b20; B.Braun, Melsungen, Germany)
in a complex medium consisting of mannitol 20 g and soybean meal 20 g in 1 l
tap water; pH was adjusted to 7.5 prior to sterilization. The fermentor was
inoculated with 5% by volume of a shake flask culture grown in a seed medium
at 27 1C in 500 ml-Erlenmeyer flasks with a single baffle for 72 h on a rotary
shaker at 120 r.p.m. The fermentation was carried out for 5 days with an
aeration rate of 0.5-volume air/volume/minute and agitation at 250 r.p.m.
Hyphlo Super-cel (2%) was added to the fermentation broth, which was
separated by multiple sheet filtration into culture filtrate and mycelium. The
culture filtrate was applied to an Amberlite XAD-16 column (resin volume
800 ml) and the resin washed with H2O and H2O–MeOH (8:2); caboxamycin
(1) was eluted with 100% MeOH and concentrated in vacuo to an aqueous
residue. The concentrate was extracted three times with ethylacetate, and the
organic extracts combined and concentrated in vacuo to dryness. The crude
product was dissolved in MeOH and applied to a diol-modified silica gel
column (402.5 cm; LiChroprep Diol, Merck, Darmstadt, Germany). 1 was
separated using a linear gradient of cyclohexane–DCM–MeOH and was eluted
with DCM–10% MeOH at a flow rate of 420 ml h1. Further purification was
achieved by chromatography on Sephadex LH-20 using MeOH–DCM (2:1)
and Toyopearl HW-40S with MeOH (each column 902.5 cm) at a flow rate of
30 ml h1.
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HPLC-DAD analyses
The chromatographic system consisted of a HP 1090M liquid chromatograph
equipped with a diode-array detector and a HP Kayak XM 600 ChemStation
(Agilent Technologies, Waldbronn, Germany). Multiple wavelength monitoring
was performed at 210, 230, 260, 280, 310, 360, 435 and 500 nm, and UV-visible
spectra were measured from 200 to 600 nm. A 10-ml aliquot of the fermenta-
tion broth was centrifuged, and the supernatant adjusted to pH 4 and extracted
with the same volume of EtOAc. After centrifugation, the organic layer was
concentrated to dryness in vacuo and resuspended in 1 ml MeOH. Here, 10ml
aliquots of the samples were injected onto an HPLC column (1254.6 mm)
fitted with a guard-column (204.6 mm) filled with 5-mm Nucleosil-100 C-18
(Maisch, Ammerbuch, Germany). The samples were analyzed by linear gradient
elution using 0.1% ortho-phosphoric acid as solvent A and MeCN as solvent B
at a flow rate of 2 ml min1. The gradient was from 0 to 100% for solvent B in
15 min with a 2-min hold at 100% for solvent B.
Structural elucidation
LC-MS experiments were performed on an Applied Biosystems QTrap 2000
(Applied Biosystems, Darmstadt, Germany) coupled to an Agilent 1100 HPLC
system (Agilent). High-resolution ESI-FT-ICR mass spectra were recorded on
an APEX II FTICR mass spectrometer (4.7 T, Bruker-Daltonics, Bremen,
Germany) and NMR experiments on a DRX 500 NMR spectrometer (Bruker,
Karlsruhe, Germany) equipped with a BBI probe head with z gradients.
Biological activity
Anti-microbial assays were performed as described earlier.26 The following
strains were used: Staphylococcus epidermidis (DSM 20044), Pseudomonas
syringae pvar. aptata (DSM 50252), Pseudomonas fluorescens (NCIMB 10586),
Xanthomonas campestris (DSM 2405), Ralstonia solanacearum (DSM 9544) and
Candida glabrata (DSM 6425).
Biofilm formation with Staphylococcus xylosus (DSM 20267) was analyzed by
a crystal violet staining assay27 in 96-well microtiter plates with the following
modifications: cells were cultivated at 37 1C instead of 30 1C; the brain heart
medium (BHI) was replaced by the trypticase soy yeast extract medium
(30 g l1 Bacto tryptic soy broth and 3 g l1 yeast extract), the cell density at
600 nm of the initial bacterial suspension was 0.01 and EtOH was used instead
of glacial acetic acid for solubilization of the incorporated dye.
The inhibitory action of caboxamycin (1) on the growth of tumor cells was
tested according to NCI guidelines28 with the human tumor cell lines AGS
(gastric adenocarcinoma), MCF7 (breast adenocarcinoma) and Hep G2 (hepa-
tocellular carcinoma). Aliquots of cell suspensions (5103 cells) were placed in
96-well microtiter plates in 0.2 ml culture medium (RPMI-1640 with 10% fetal
calf serum) and incubated in a humidified atmosphere of 5% CO2 in air. After
24 h caboxamycin (1) (0.1B10mg ml1) and UK-1 (2) (0.1B10mg ml1) as
positive control were added to the cells and the cells cultivated for additional
48 h. The cell count was surveyed by protein determination with sulforhoda-
mine B. From the resulting concentration–activity curves, the GI50 (concentra-
tion at which half of the cells were inhibited in their growth) and TGI
(concentration at which a total inhibition of cell growth was observed) values
were obtained.
Analysis of the effect of 1 on human recombinant cAMP-specific phospho-
diesterase (PDE-4B2) was carried out with final concentrations of the substance
of 488mM (125mg ml1) in 50 mM Tris-HCl buffer (pH 7.5) containing 8.3 mM
MgCl2, 1.7 mM EGTA and 10 mU recombinant human cAMP-specific PDE 4B2
(Merck Bioscience 524736-10U, Darmstadt, Germany) in a volume of 20ml per
well. The reaction was started with 20ml of 40mM cAMP (Sigma A9501,
Taufkirchen, Germany) dissolved in 50 mM Tris-HCl (pH 7.5) containing
8.3 mM MgCl2 and 1.7 mM EGTA. After an incubation period of 30 min at
30 1C the reaction was stopped and the AMP concentration was quantified with
the PDELight HTS cAMP Phosphodiesterase Assay Kit (Lonza, LT07-600,
Wuppertal, Germany) according to the instructions of the supplier. The lumines-
cence was measured using the microtiter plate reader Infinite M200 (Tecan,
Crailsheim, Germany) with 0.1 s integration time. For inhibition of the PDE,
100mM of Rolipram (4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone)
(Merck Bioscience Cat.No. 557330) were used as a positive control. The effect of 1
on PDE activity from bovine brain (a mixture of three isoforms PDE-2, PDE-4
and PDE-10) was tested accordingly. 10 mM Tris-HCl buffer (pH 7.4) was used
containing 1 mU (1ml) of 3,5-cyclic-nucleotide-specific PDE from bovine brain
(Sigma P9529)29 in a total volume of 20ml, and the reaction was started with
20ml of 40mM cAMP (Sigma A9501) solution in 10 mM Tris-HCl pH 7.4.
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